title: Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
abstract: Bone is a common site for tumor spread in patients with solid tumors. So far bisphosphonates have been the main pharmacological treatment option for patients with bone metastases. We present a case of bone metastatic gastric cancer treated with zoledronic acid at first and later with denosumab. After 1 year of denosumab treatment, the 18F-fluorodeoxyglucose (18F-FDG)-PET/computed tomography scan reassessment documented a metabolic complete response, even in the absence of specific antiblastic treatment. Whether denosumab can be used directly after pretreatment with bisphosphonates has yet to be addressed.
authors.affiliation: aRare Tumors Unit bRadiotherapy and Nuclear Medicine Unit cFamiliar Cancer Clinic, Veneto Institute of Oncology, IRCCS, Padua, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Cappetta
authors.forename: Laura
authors.initials: L
authors.lastname: Spano
authors.forename: Laura
authors.initials: L
authors.lastname: Evangelista
authors.forename: Stefania
authors.initials: S
authors.lastname: Zovato
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Opocher
authors.forename: Davide
authors.initials: D
authors.lastname: Pastorelli
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D019788:Fluorodeoxyglucose F18; D000069448:Denosumab; D000077211:Zoledronic Acid